AbbVie Wins Canada Reimbursement Backing for Adult Migraine Treatment

Regulation
โดย Simply Wall St·CAUS·Read original
Summary · why it matters

AbbVie received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision follows Phase 3 trial results and a review process that included direct input from patients and clinicians. The recommendation expands access to UBRELVY in Canada and broadens AbbVie's neuroscience portfolio in migraine care.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
AbbVie Inc
ABBV
▲ PositiveDemandrelevance

Canada's Drug Agency recommends reimbursement for UBRELVY, expanding access and boosting demand for AbbVie's migraine treatment.

© 2026 MarketDXNews